Candesartan plus hydrochlorothiazide fixed combination vs previous monotherapy plus diuretic in poorly controlled essential hypertensive patients

Giuseppe Mancia, Stefano Omboni

Research output: Contribution to journalArticlepeer-review

Abstract

Objective: To assess efficacy and tolerability of candesartan cilexetil (CC) plus hydrochlorothiazide (HCTZ) fixed combination vs previous monotherapy (PM) plus HCTZ in hypertension. Design and Methods: After 2-4 weeks of run in, 409 outpatients (diastolic blood pressure, DBP >90 and ≤110 mmHg; systolic blood pressure, SBP ≤180mmHg), aged 26-79 years, under monotherapy, were randomized in a PROBE multicenter trial to CC 16 mg plus HCTZ 12.5 mg or PM plus HCTZ 12.5 mg for 8 weeks. HCTZ was doubled after the first 4 weeks in non-responders (DBP ≥90 mmHg or SBP >180 mmHg). Results: Automatic oscillometric (Omron 705 CP) DBP and SBP were similarly reduced by CC + HCTZ and PM + HCTZ after 4 (12/15 and 10/13 mmHg) and 8 weeks (13/20 and 12/18 mmHg) in the intention-to-treat (ITT, n = 398) population. HCTZ dose was doubled in 18.1 and 31.2% of patients in the CC + HCTZ and PM + HCTZ group, respectively (p <0.05). Rate of normalized patients (DBP

Original languageEnglish
Pages (from-to)11-17
Number of pages7
JournalBlood Pressure, Supplement
Volume13
Issue number2
DOIs
Publication statusPublished - Dec 2004

Keywords

  • ACE inhibitors
  • Antihypertensive treatment
  • Beta-blockers
  • Calcium antagonists
  • Candesartan
  • Essential hypertension
  • Hydrochlorothiazide

ASJC Scopus subject areas

  • Internal Medicine
  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Candesartan plus hydrochlorothiazide fixed combination vs previous monotherapy plus diuretic in poorly controlled essential hypertensive patients'. Together they form a unique fingerprint.

Cite this